AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04259814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy (mCIMT)
Description: Participants will wear a removable cast and an occupational therapist will be present during therapy to focus on facilitating play with the affected arm.
Study NCT04259099 — intervention group
Intervention type: OTHER
Intervention: Testing the Quality of Life Questionnaire of the European Foundation for Osteoporosis-31(QUALEFFO-31)
Description: Administer the questionnaires to 150 participants to classify their status of quality of life.
Study NCT01378585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: 3 x 490 mg DLBS1033 daily
Study NCT01378585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 1 tablet daily
Study NCT04176471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Therapeutic hypothermia involves use of a servo-controlled device and blanket to lower the core body temperature by 3°C for 72 hours followed by a period of re-warming in which the temperature is increased by 0.5°C per hour for 6 hours until normothermia is achieved.
Study NCT04176471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normothermia
Description: Normothermia will be achieved using the same servo-controlled device and blanket to assure normothermia of the control arm. The goal temperature for normothermia is 36.5-37.3°C for 72 hours.
Study NCT04070872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D laparoscope
Description: For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
Study NCT04070872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D laparoscope
Description: For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
Study NCT04359316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04359316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study NCT04359316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Azithromycin in COVID-19 patients.
Study NCT01921595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Valanced salt colloid
Description: Maximum dose : 30ml/kg, IV, The infusion of valanced salt colloid is started at bleeding and continued until reach at maximum dose
Study NCT01921595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Valanced salt crystalloid group
Description: Maximum dose : 30ml/kg, IV, The infusion of valanced salt crystalloid is started at bleeding and continued until reach at maximum dose
Study NCT00755183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone ophthalmic solution
Description: testosterone ophthalmic solution for 128 days
Study NCT00755183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of testosterone ophthalmic solution
Description: vehicle of testosterone ophthalmic solution for 128 days
Study NCT01547078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized Plasma
Description: Licensed plasma that has been lyophilized.
Study NCT01547078 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Plasma
Description: Plasma that has been authorized for transfusion.
Study NCT04122716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Daily injections (3mg) with weight consultations starting at dose of 0.6 mg injections with 0.6 mg increments weekly until 3.0 mg is achieved. For subjects who do not tolerate the fast weekly up-titration of 0.6 mg study drug until the 3mg, the titration procedure can be prolonged with up to three weeks for each up-titration.~Subjects who do not tolerate the 3mg dose may in special circumstances stay at 2.4 mg, however the overall aim is to reach 3 mg for all study subjects.~The dosage and up-titration follow the recommendations from the summary of product characteristics.
Study NCT04122716 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liraglutide
Description: Daily injections (3mg) with weight consultations starting at dose of 0.6 mg injections with 0.6 mg increments weekly until 3.0 mg is achieved. For subjects who do not tolerate the fast weekly up-titration of 0.6 mg study drug until the 3mg, the titration procedure can be prolonged with up to three weeks for each up-titration.~Subjects who do not tolerate the 3mg dose may in special circumstances stay at 2.4 mg, however the overall aim is to reach 3 mg for all study subjects.~The dosage and up-titration follow the recommendations from the summary of product characteristics.
Study NCT04122716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations.~Exercise prescription will be performed under strict control of the scientific personnel.~There will be aerobic exercise and will include 4 sessions per week after the ramp-in period.~2 sessions per week will be performed under supervision of the staff and 2 sessions will be performed individually but monitored by the staff.~Supervised sessions include structured exercise with a duration of 45 min. Of this 30 min will comprise of interval-based spinning session and 15 min circuit training program focusing on large muscle groups.~Individual exercise includes aerobic exercise and general physical activity (e.g brisk walking and cycling to work).~Participants will use heart rate monitors during sessions.
Study NCT04122716 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations.~Exercise prescription will be performed under strict control of the scientific personnel.~There will be aerobic exercise and will include 4 sessions per week after the ramp-in period.~2 sessions per week will be performed under supervision of the staff and 2 sessions will be performed individually but monitored by the staff.~Supervised sessions include structured exercise with a duration of 45 min. Of this 30 min will comprise of interval-based spinning session and 15 min circuit training program focusing on large muscle groups.~Individual exercise includes aerobic exercise and general physical activity (e.g brisk walking and cycling to work).~Participants will use heart rate monitors during sessions.
Study NCT02398435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tadekinig alfa (recombinant human IL-18 binding protein)
Description: Patients received the study treatment three times a week subcutaneously.
Study NCT04674423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Tenofovir Alafenamide treatment for 144 weeks
Study NCT00110747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
Description: S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
Study NCT00110747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Peel
Description: Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
Study NCT02397161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG biofeedback mental attention-neuromuscular training
Description: Mental attention training using EEG biofeedback and neuromuscular training using physio-therapeutic exercises
Study NCT02397161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: Neuromuscular training using physio-therapeutic exercises
Study NCT02397161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG biofeedback mental attention training
Description: Mental attention training using EEG biofeedback
Study NCT01911494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Engagement
Description: The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,
Study NCT01911494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PIERS on the Move mHealth decision aid
Description: This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (>160mmHg systolic) or proteinuria (>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
Study NCT01083771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: Minimum of 3 tablespoon of olive oil per day
Study NCT04446884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem cells
Description: Autologous adipose-derived mesenchymal stem cells mixed with collagen solution
Study NCT04446884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols
Study NCT04446884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols
Study NCT04089995 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: No intervention
Study NCT01323101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
Study NCT01323101 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No doxycycline
Study NCT04188561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra articular injection Group
Description: Patients included in the study had been received 2 ml high molecular weight (1.476 x 106 average Daltons) hyaluronic acid with concentration of 22mg/ml (OPTIVISC UK hyaluronic acid for intra articular injection). Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval. 3 distinct layers are produced by the end of the centrifugation: plasma, buffy coat (platelet) and RBCs, about 3 - 3.5 ml of PRP is produced~at the end with platelet concentration of 1.4 - 1.6 million/μl on average.
Study NCT04188561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Group
Description: Thermal radiation is done by Neurotherm 2000 (Neurotherm NT 2000 Radiofrequency (RF) Generator is a four electrode pain management (RF) generator for interventional pain management procedures. Neurotherm's newest system offers accurate independent controls of each electrode through the touch screen interface and output control knobs.), Patients from the radiofrequency (RF) group had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
Study NCT01411046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Synacthen test
Description: 250 microg Synacthen test, performed fasting, in the morning, starting between 08·00 and 10·30 h, after an overnight fast and a prednisolone pause of approximately 48 hours (depending on normal dose administration time).
Study NCT00553878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dutasteride
Description: dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
Study NCT01999257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online pre-test genetic education tool
Description: See Arm Descriptions above.
Study NCT02644499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
Study NCT02644499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
Study NCT02644499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
Study NCT02644499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
Study NCT02644499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
Study NCT01054885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF Inhalation Powder
Description: Inhaled Corticosteroid (ICS)
Study NCT01054885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Study NCT01054885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 Inhalation Powder
Description: Long Acting Beta Agonist(LABA)
Study NCT01054885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04433676 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT02256280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex will be diluted in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 4 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 2 mg/kg
Study NCT02256280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 0.07 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 0.05 mg/kg Atropine will be administered at a 0.02 mg/kg dosage.
Study NCT03599739 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza
Description: Facilities will be asked to complete a survey to evaluate the impact of the influenza vaccine choice on hospitalization risk for the 2017-2018 influenza season.
Study NCT00938067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staying Connected
Description: The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
Study NCT01432730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Oral tablets, BID
Study NCT01432730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets, BID
Study NCT02534740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: relative bioavailability
Study NCT02534740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: fasted
Study NCT02534740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: fed
Study NCT04841083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allay Lamp
Description: The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10 lux) narrow band (20 nm) green light (peak wavelength 520 nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k).
Study NCT02668562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early CABG (Day 2-3 after ticagrelor discontinuation)
Description: Timing for CABG after ticagrelor discontinuation
Study NCT02668562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed CABG (Day 5-7 after ticagrelor discontinuation)
Description: Timing for CABG after ticagrelor discontinuation
Study NCT00940953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide + Azelastine
Description: nasal spray, one spray per nostril at time 0 plus one spray Placebo
Study NCT00940953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide + Azelastine
Description: nasal spray, one spray of each per nostril at time 0
Study NCT00940953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nasal spray, one spray per nostril from each of 2 bottles at time 0
Study NCT01536886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100
Study NCT01536886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone plus calcipotriol
Study NCT01536886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ointment vehicle
Study NCT01536886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 vehicle
Study NCT04266145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous dexmedetomidine
Description: adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL normal saline while, the intravenous solution; consists of 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline
Study NCT04266145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block dexmedetomidine
Description: adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL of 0.5µg.kg-1 dexmedetomidineline while, the intravenous solution;consists of 20 mL normal saline
Study NCT01707732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Administration of Enoxaparin
Study NCT01707732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Administration of Enoxaparin
Study NCT01515553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
Study NCT05812872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toothgraft
Description: Particulate dentin
Study NCT05812872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: Mineralized corticocancellous allograft
Study NCT05812872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alloplast
Description: Beta tri-calcuim phosphate
Study NCT02183649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxyverine citrate
Study NCT02183649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03729700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond
Description: The almond dose will be provided as 20% of total energy (20% E) in the diet.
Study NCT01216553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Therapy
Description: 1 lt/min oxygen via nasal cannulae intermittently for 30 minuets 4 times daily for 7 days
Study NCT02492763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521
Description: Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen \[60 μg, 120 μg\] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen \[60 μg, 120 μg, 180 μg\] over the first 3 weeks is used to achieve the final dose up to 300 μg.